MDxHealth reported preliminary fourth quarter 2024 revenues of approximately $24.7 million, representing a 28% increase year-over-year. For the full year 2024, preliminary revenues are expected to be approximately $90.0 million, also marking a 28% year-over-year growth.
The company's test volumes showed significant increases in the fourth quarter, with tissue-based units growing 50% to 11,789 units and liquid-based units increasing 10% to 12,036 units. For the full year, tissue-based units grew 31% to 41,586, and liquid-based units grew 28% to 45,700.
MDxHealth issued 2025 revenue guidance in the range of $108-110 million, which represents a year-over-year growth of 20-22%. The company also confirmed its expectation of achieving adjusted EBITDA profitability in the first half of 2025. The cash balance at year-end 2024 was $46.8 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.